ArticleJournal of medicinal chemistry2025
Design, Synthesis, and Cellular Characterization of a New Class of IPMK Kinase Inhibitors.
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Host soluble inositol phosphate signaling promotes coronavirus replication.bioRxiv : the preprint server for biology · 2026Article
- Structural insights into the development of inhibitors for inositol phosphate kinases.FEBS letters · 2026Review
- IPMK at the crossroads of cellular signaling in health and disease.FEBS letters · 2026Review
- Suppression of ITPK1 and IPMK activities impairs mTORC1 signaling in pancreatic β-cells and implicates IPbioRxiv : the preprint server for biology · 2026Article
- Structural Rationalization of IPMK Inhibitor Potency.Journal of medicinal chemistry · 2025Article
- Synthesis of a New Purine Analogue Class with Antifungal Activity and Improved Potency against Fungal IPACS infectious diseases · 2025Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
The kinase activity of human inositol phosphate multikinase (IPMK) is required for the synthesis of higher-order inositol phosphate signaling molecules, regulation of gene expression, and control of the cell cycle. Here, we report a novel series of highly potent IPMK inhibitors. The first-generation IPMK inhibitor
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.